Stock vs Stock Comparison

Merck & Co., Inc. vs AbbVie Inc.

MRK wins the Tale of the Tape 5–4.

MRK$115.65
ABBV$215.40

🏆 Tale of the Tape

54
MRKABBV
28.1%Profitability (Net Margin)6.9%
33.4xValuation (P/E)106.2x
16.3%Efficiency (ROIC)8.3%
4/9Health (Piotroski F)7/9
4.0Safety (Altman Z)2.0
1.3%Growth (Rev YoY)8.6%
1.43Risk (Sharpe 1Y)0.61
1.60xBalance Sheet (D/E)-42.50x
3.72%FCF Yield4.23%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.528
252-Day Correlation
0.339
126-Day Correlation

Moderately correlated — some diversification benefit from holding both.

Fundamentals

MetricMRKABBV
Market Cap$293.2B$384.7B
P/E Ratio33.4x106.2x
Forward P/E12.4x13.4x
P/B6.39x-57.80x
Dividend Yield2.86%3.18%
Beta0.200.30

Quantitative Metrics

MetricMRKABBV
DCF Fair Value$96.93$126.26
DCF Upside-19.3%-38.9%
Piotroski F4/97/9
Altman Z4.042.01
Beneish M-2.27-2.87
FCF Yield3.72%4.23%
Net Debt/EBITDA1.1x3.0x
ROIC16.3%8.3%
WACC7.4%7.4%
ROIC – WACC8.9pp0.8pp
Gross Margin74.8%70.2%
Net Margin28.1%6.9%
Rev Growth YoY1.3%8.6%
Sharpe (1Y)1.430.61
Max Drawdown 3Y
FCF Payout Ratio66%65%

MRK Price

Loading chart...

ABBV Price

Loading chart...

ETF Exposure

MRK found in:

XLV5.37%
IYH4.97%
VHT4.39%
SCHD4.24%
XPH1.82%
MOAT1.52%
DIA1.42%
MGV1.34%
QUS1.24%
VIG1.22%
DVY1.22%
VYM1.13%
VTV1.05%
SCHV1.04%
DGRW1.03%
SPYV1.00%
IWD0.98%
VONV0.83%
VFVA0.72%
ESGV0.60%
SCHX0.49%
SCHB0.46%
SPY0.45%
IVV0.45%
VOO0.44%
VFMO0.44%
SPTM0.42%
VONE0.41%
ITOT0.39%
VTI0.39%
SPLG0.37%
URTH0.36%
ACWI0.29%
VT0.24%
RSP0.22%
ONEO0.12%
VGK0.11%
SPDW0.06%
VSGX0.06%
CWI0.06%
VEA0.05%
VXUS0.04%
VEU0.04%

ABBV found in:

XLV7.07%
IYH6.86%
VHT6.04%
HDV5.61%
SCHD3.53%
DGRO2.52%
DGRW1.99%
MGV1.85%
VIG1.68%
VYM1.56%
NOBL1.49%
VTV1.46%
SDY1.42%
IWF1.39%
SCHV1.38%
VONG1.21%
XBI1.09%
ESGV0.78%
SPYV0.71%
IVV0.69%
SPLG0.68%
SCHX0.66%
SCHB0.62%
ITOT0.61%
VOO0.60%
SPY0.59%
VONE0.57%
SPTM0.55%
VTI0.54%
SPYG0.50%
URTH0.48%
ACWI0.41%
VFVA0.41%
VT0.33%
QUS0.32%
VFMV0.25%
RSP0.19%
ONEO0.03%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

MRK vs ABBV: Head-to-Head Analysis

Merck & Co., Inc. (MRK) and AbbVie Inc. (ABBV) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, MRK leads 5–4 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, MRK generates a return on invested capital (ROIC) of 16.3% compared to ABBV's 8.3%. This suggests MRK is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between MRK and ABBV is 0.528, indicating moderate co-movement, with some diversification value from holding both in a portfolio context.

MRK appears in 43 ETFs tracked by SecuritiesDB, while ABBV appears in 38 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, MRK or ABBV?

Our quantitative analysis compares MRK and ABBV across nine fundamental dimensions. MRK wins the Tale of the Tape 5–4. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are MRK and ABBV correlated?

The 252-day correlation between MRK and ABBV is 0.528. They show moderate correlation — partially diversifying.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.